中國生物製藥(01177.HK)"依達拉奉氯化鈉注射液"新增適應症申請獲受理
格隆匯2月20日丨中國生物製藥(01177.HK)公告,公司附屬公司江蘇正大豐海製藥有限公司研製的腦神經保護劑"依達拉奉氯化鈉注射液"(商品名稱:依必坦),已向中華人民共和國國家藥品監督管理局提交新增適應症申請並獲得受理,申請新增的適應症為:肌萎縮性脊髓側索硬化。
ALS是一種不可逆性、致死性的運動神經元疾病,由於患者大腦、腦幹和脊髓中運動神經細胞受到侵襲,患者逐漸出現肌無力以至癱瘓,漸漸失去説話甚至是吞嚥能力,最終因呼吸衰竭導致死亡。
依達拉奉可清除自由基,避免血管內皮細胞、神經細胞的氧化損傷,是一種有效的腦神經保護劑。在美國、日本、中國等地,依達拉奉是目前少數獲批用於治療ALS的藥物一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.